Preview

Rational Pharmacotherapy in Cardiology

Advanced search

FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW

https://doi.org/10.20996/1819-6446-2014-10-4-416-420

Full Text:

Abstract

Strategies for the management of patients with atrial fibrillation (heart rhythm or heart rate control) are considered. The advantages of these methods, especially the implementation are presented. Based on their own data, authors give an algorithm to select the management strategy in particular patient. Preparation and implementation of electrical cardioversion procedure are described. The evidence base and analysis of complications of different anticoagulants use for safety of sinus rhythm restoration are presented.

About the Authors

S. A. Zenin
Novosibirsk Regional Clinical Cardiology Clinic
Russian Federation
Zaleskogo ul. 6-8, Novosibirsk, 630047 Russia


A. V. Fedoseenko
Novosibirsk Regional Clinical Cardiology Clinic
Russian Federation
Zaleskogo ul. 6-8, Novosibirsk, 630047 Russia


O. V. Kononenko
Novosibirsk Regional Clinical Cardiology Clinic
Russian Federation
Zaleskogo ul. 6-8, Novosibirsk, 630047 Russia


O. V. Pyataeva
Novosibirsk Regional Clinical Cardiology Clinic
Russian Federation
Zaleskogo ul. 6-8, Novosibirsk, 630047 Russia


References

1. RSC, RSSA, RACVS guidelines for the electrophysiological studies, catheter ablation and implantable use of antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/Recomend2013.pdf. Accessed by 15/08/2014. Russian (Клинические рекомендации РКО, ВНОА И АССX по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Доступно на: http://www.vnoa.ru/literature/Recomend2013.pdf. Проверено 15.08.2014).

2. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-6.

3. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/ Paisley study. Heart 2001; 86: 516-21.

4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.

5. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.

6. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-9.

7. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-17.

8. Knecht S, Oelschlager C, Duning T, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29: 2125-32.

9. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-75.

10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20- year follow-up of the Renfrew/ Paisley study. Am J Med 2002; 113: 359-64.

11. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-26.

12. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119: 448 e1-e19.

13. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.

14. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.

15. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-77.

16. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-83.

17. Khan MN, Jais P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778-85.

18. Berge E, Atar D, Le Heuzey JY et al. Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD registry. Eur Heart J 2013; 34 suppl 1: P551.

19. Tatarskii BA, Nefedova NV. Electric external cardioversion of atrial fibrillation in the treatment of paroxysmal presderdy. Arrhythmology Bulletin 2000; 19: 95-9. Russian (Татарский Б.А., Нефедова Н.В.

20. Электрическая наружная кардиоверсия при лечении пароксизмальной фибрилляции пресдердий. Вестник Аритмологии 2000; 19: 95-9).

21. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke 2009; 40: 1410-6.

22. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus Warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.

23. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial. Journal of the American College of Cardiology. 2014;63(11):1082-1087

24. Chung MK, Shemanski L, Sherman DG, et al. Functional Status in Rate- Versus Rhythm-Control Strategies for Atrial Fibrillation. Results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005; 15(46):1891-9.

25. Popov SV, Aubakirova GA, Antonchenko IV, et al. Efficacy of class III antiarrhythmic drug nibentan in patients with atrial fibrillation. Arrhythmology Bulletin, 2003; 31: 10-4. Russian (Попов С.В., Аубакирова Г.А., Антонченко И.В. и др. Эффективность антиаритмического препарата III класса нибентана у больных с фибрилляцией предсердий. Вестник Аритмологии 2003; 31: 10-4).

26. Vostrikova VA. Efficacy and safety of cardioversion of atrial fibrillation. In: Nazirov RZ, eds. Methods of nonlinear analysis in cardiology and oncology. Moscow: KDU; 2010: 73- 79. Russian (Востриков В.А. Эффективность и безопасность электроимпульсной терапии фибрилляции предсердий. В: Назиров Р.З., ред. Методы нелинейного анализа в кардиологии и онкологии. М. : КДУ; 2010: 73-79).


For citation:


Zenin S.A., Fedoseenko A.V., Kononenko O.V., Pyataeva O.V. FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW. Rational Pharmacotherapy in Cardiology. 2014;10(4):416-420. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-4-416-420

Views: 335


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)